Eisai receives FDA approval for BANZEL Oral Suspension to treat seizures linked with LGS

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BANZEL^® (rufinamide) Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children 4 years and older and adults. The oral suspension formulation is bioequivalent to the currently marketed BANZEL tablet formulation on a milligram per milligram basis and will be available for prescription use by late March 2011.

"This new formulation provides an option for patients who may prefer a liquid or find it difficult to take the medication in tablet form," said Lonnel Coats, president and CEO of Eisai Inc. "The development of an oral suspension formulation further exemplifies Eisai's human health care (hhc) mission of keeping patients' needs at the forefront of all that we do."